PRODUCT INFORMATION



HLA-A2 mAb (BB7.2), InVivoPure+

Endotoxin level ≤ 1 EU/mg

Description:

The BB7.2 monoclonal antibody is a well-characterized mouse IgG2b antibody that specifically recognizes HLA-A2, a major histocompatibility complex (MHC) class I molecule found in humans. This antibody is widely used in immunological research, transplantation studies, and cancer immunotherapy.

BB7.2 binds to a conformational epitope of the HLA-A2 heavy chain, typically in association with β 2-microglobulin (β 2m). It does not cross-react with other HLA class I alleles, making it a valuable tool for distinguishing HLA-A2+ cells from non-HLA-A2+ populations [1].

HLA-A2 is an important molecule in tumor immunology, as many tumor-associated antigens (e.g., NY-ESO-1, MART-1) are presented by HLA-A2 to cytotoxic T lymphocytes (CTLs). The BB7.2 antibody serves as a critical reagent in screening and validating HLA-A2-restricted T-cell responses in cancer vaccine and T-cell therapy research [2].

The HLA-A2 mAb (BB7.2) can be used in Flow cytometry, immunoprecipitation and Western Blot, immunohistochemistry and functional blocking assay.

This antibody is produced exclusively under serum-free conditions from hybridoma and purified with Protein-A or Protein-G affinity chromatography.

Product-ID: AK3625P+

Clone: BB7.2

Immunogen: Papain solubilized HLA-A2

Host: Mouse

Clonality: Monoclonal

Isotype: Mouse IgG2b

Formulation: Clear Liquid, PBS, pH 7.4, 0.2 μm sterile filtered

Concentration: ≥ 1.00 mg/mL

Purity: ≥ 95 % (CGE, reducing conditions)

≤ 5 % aggregates (analytical SEC)

Endotoxin: ≤ 1 EU/mg (LAL test)

Storage: 2 - 8 °C

Recommended Isotype Control: Mouse IgG2b κ Isotype Control (AK3456P+)

Reported Application: FACS ; IHC ; IF ; Fn

The product is for research use only and not for use in diagnostic or therapeutic procedures.

InVivo BioTech Services GmbH is certified to <u>ISO 9001</u> and <u>ISO 13485</u>.

Literature:

PRODUCT INFORMATION




- [1] Parham P, Bodmer WF. Monoclonal antibody to a human histocompatibility alloantigen, HLA-A2. Nature. 1978 Nov 23;276(5686):397-9. doi: 10.1038/276397a0. PMID: 714164.
- [2] Zhang HG, Chen HS, Peng JR, Shang XY, Zhang J, Xing Q, Pang XW, Qin LL, Fei R, Mei MH, Leng XS, Chen WF. Specific CD8(+)T cell responses to HLA-A2 restricted MAGE-A3 p271-279 peptide in hepatocellular carcinoma patients without vaccination. Cancer Immunol Immunother. 2007 Dec;56(12):1945-54. doi: 10.1007/s00262-007-0338-8. Epub 2007 May 24. PMID: 17522859; PMCID: PMC11030141.


PRODUCT INFORMATION



HLA-A2 mAb (BB7.2), InVivoPure+ — Supplementary Data


Analytical SEC:





Analytical SEC of purified protein (blue) in comparison with gel filtration standard (red).

Capillary gel electrophoresis:



CGE of the purified protein under reducing (red.) conditions.